Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

Discovery and saturation analysis of cancer genes across 21 tumour types

Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096

Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351

The dual role of p63 in cancer

Xu, Y., Yang, X., Xiong, Q., Han, J., & Zhu, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116061 · Cited by 19

Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Wang, D., Yan, K. H., Yu, H., Li, H., Zhou, W., Hong, Y., Guo, S., Wang, Y., Xu, C., Pan, C., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0394 · Cited by 18

A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers

Alruwaili, M., Zonneville, J., Naranjo, M. N., Serio, H., Melendy, T., Straubinger, R. M., Gillard, B. M., Foster, B. A., Rajan, P., Attwood, K. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101434 · Cited by 18

Current insights and future directions of Li-Fraumeni syndrome

Hosseini, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01435-w · Cited by 21

Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis

Wang, Y., Wu, W., Su, Y.-N., Ai, Z., Mou, H.-C., Wan, L.-S., Luo, Y., Qiu, M., & Zhang, J. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153187 · Cited by 17

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

Tang, F. R., Pan, Z., Wang, Y., Lan, T., Wang, M., Li, F., Quan, W., Liu, Z., Wang, Z., & Li, Z. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00866-1 · Cited by 18

Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy

Timofeev, O. N., & Stiewe, T. (2021) · Cancers · doi:10.3390/cancers13102422 · Cited by 18

P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer

Laka, K., & Mbita, Z. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.876213 · Cited by 17

DNA Replication Stress Induced by Trifluridine Determines Tumor Cell Fate According to p53 Status

Kataoka, Y., Iimori, M., Fujisawa, R., Morikawa, T., Niimi, S., Wakasa, T., Saeki, H., Oki, E., Miura, D., Tsurimoto, T., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1051 · Cited by 16

Extrinsic induction of apoptosis and tumor suppression via the p53–Reprimo–Hippo–YAP/TAZ–p73 pathway

Takikawa, M., Nakano, A., Krishnaraj, J., Tabata, Y., Watanabe, Y., Okabe, A., Sakaguchi, Y., Fujiki, R., Mochizuki, A., Tajima, T., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413126122 · Cited by 16

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies

Dietz, M. V., van Kooten, J. P., Paats, M. S., Aerts, J. G. J. V., Verhoef, C. K., Madsen, E. V. E., Dubbink, H. J., & von der Thüsen, J. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101600 · Cited by 18

Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia

Wang, K., Jiang, M., Liu, H., Meng, C., Li, M., & Lu, H. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107319 · Cited by 17

p53 functional loss, stemness and hepatocellular carcinoma

de Fromentel, C. C., & Levrero, M. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.77 · Cited by 16

Development of TP53 mutations over the course of therapy for acute myeloid leukemia

Alwash, Y., Khoury, J. D., Tashakori, M., Kanagal‐Shamanna, R., Daver, N. G., Ravandi, F., Kadia, T. M., Konopleva, M. Y., Dinardo, C. D., Issa, G. C., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26314 · Cited by 16

OTUD7B is a new deubiquitinase targeting p53

Ding, C., Cao, L., Wang, R., Wu, Q., Li, M., Zhang, J., Thorne, R. F., Li, J., Ma, J., Wu, M., et al. (2025) · Theranostics · doi:10.7150/thno.103012 · Cited by 16

Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics

Cui, X., Huang, T., Jiang, T., & Wang, H. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217540 · Cited by 18

Cannabinol inhibits cell growth and triggers cell cycle arrest and apoptosis in cancer cells

Zhong, N., Li, D., Wang, B., Kovalchuk, O., & Kovalchuk, I. (2023) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2023.102627 · Cited by 15

Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations

Baranwal, A., Langer, K. J., Gannamani, V., Rud, D., Cibich, A., Saygin, C., Nawas, M. T., Badar, T., Kharfan‐Dabaja, M. A., Ayala, E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015335 · Cited by 15

The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

Omar, S. I., & Tuszyński, J. A. (2018) · Oncotarget · doi:10.18632/oncotarget.26440 · Cited by 15

p53-Related Transcription Targets of TAp73 in Cancer Cells—Bona Fide or Distorted Reality?

Wang, C., Teo, C. R., & Sabapathy, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041346 · Cited by 15

Role of oncogenic REGγ in cancer

Shen, M., Wang, Q., Xu, S., Chen, G., Xu, H. Y., Li, X., & Zhao, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110614 · Cited by 15

Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53–R175H mutant aggregation

Lei, J., Cai, M., Shen, Y., Lin, D., & Deng, X. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp03094a · Cited by 15

EFMC: Trends in Medicinal Chemistry and Chemical Biology

Auberson, Y. P., Arimondo, P. B., Duca, M., Essig, S., Grether, U., Rufer, A. C., Sbardella, G., Schopfer, U., Torrens, A., van der Stelt, M., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202200690 · Cited by 16

Cancer surveillance for individuals with Li-Fraumeni syndrome

Kratz, C. P., Villani, A., Nichols, K. E., Schiffman, J. D., & Malkin, D. M. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-00709-5 · Cited by 15

Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells

Ciccone, M. A., Adams, C. L., Bowen, C. M., Thakur, T., Ricker, C. N., Culver, J. O., Maoz, A., Melas, M., Idos, G., Jeyasekharan, A. D. D., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.040 · Cited by 15

A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer

Miller, J. J., Kwan, K., Gaiddon, C., & Storr, T. (2022) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-022-01939-2 · Cited by 14

p53 inhibits CTR1-mediated cisplatin absorption by suppressing SP1 nuclear translocation in osteosarcoma

Yong, L., Shi, Y., Wu, H.-L., Dong, Q.-Y., Guo, J., Hu, L.-S., Wang, W., Guan, Z.-P., & Yu, B.-S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1047194 · Cited by 14

Pharmacogenetic and pharmacogenomic discovery strategies

Crisafulli, C., Romeo, P. D., Calabrò, M., Epasto, L. M., & Alberti, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.008 · Cited by 14

Potential oncogenic roles of mutant-p53-derived exosomes in the tumor–host interaction of head and neck cancers

Azulay, E. E., Cooks, T., & Elkabets, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02450-5 · Cited by 14

Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib

Lu, J., Hu, Y., Qian, R., Zhang, Y., Yang, X., & Luo, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173022 · Cited by 14

Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells

Strobel, S. B., Machiraju, D., Hülsmeyer, I., Becker, J. C., Paschen, A., Jäger, D., Wels, W. S., Bachmann, M. P., & Hassel, J. C. (2021) · Life · doi:10.3390/life11040269 · Cited by 15

Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab

Ruzzo, A., Graziano, F., Bagaloni, I., Bartolomeo, M. D., Prisciandaro, M., Aprile, G., Ongaro, E., Vincenzi, B., Perrone, G., Santini, D., et al. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01078-0 · Cited by 14

TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors

Morabito, F., Gentile, M., Monti, P., Recchia, A. G., Menichini, P., Skafi, M., Atrash, M., Luca, G. D., Bossio, S., Al‐Janazreh, H., et al. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1783239 · Cited by 13

SOHO State of the Art Updates and Next Questions | Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway

Maiti, A., Carter, B. Z., Andreeff, M., & Konopleva, M. Y. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.04.001 · Cited by 13

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations

Canale, M., Petracci, E., Cravero, P., Mariotti, M., Minuti, G., Metro, G., Ludovini, V., Baglivo, S., Puccetti, M., Dubini, A., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101471 · Cited by 16

Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials

Wang, M., Yang, Z., Song, Y., Wei, P., Ishimwe, N., Wang, L., Zhang, H., Jing, M., Gao, M., Wen, L., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.07.057 · Cited by 13

Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations

Li, B., Mascarenhas, J. O., & Rampal, R. K. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0491-5 · Cited by 13

Arsenic concentration in topsoil of central Chile is associated with aberrant methylation of P53 gene in human blood cells: a cross-sectional study

Eva Madrid, A., González, I., Muñoz, S., Rejas, C., Cardemil, F., Martínez, F. T., Cortes, J. P., Berasaluce, M., & Párraga, M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-19085-2 · Cited by 13

AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity

Liang, Y., An, Q., Song, H., Tang, Y., Xiao, S., Wu, J., Yan, N., Yu, B., Cao, X., & Lu, M. M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00104 · Cited by 12

Unveiling the distinctive variations in multi-omics triggered by TP53 mutation in lung cancer subtypes: An insight from interaction among intratumoral microbiota, tumor microenvironment, and pathology

Tong, S., Huang, K., Xing, W., Chu, Y., Nie, C., Ji, L., Wang, W., Tian, G., Wang, B., & Yang, J. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108274 · Cited by 14

Linc-ROR promotes arsenite-transformed keratinocyte proliferation by inhibiting P53 activity

Li, X., Zuo, C., Wu, M., & Zhang, Z. (2020) · Metallomics · doi:10.1039/d0mt00076k · Cited by 12

Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas

Desai, C., Thomason, J., Kohlmeyer, J. L., Reisetter, A. C., Ahirwar, P., Jahanseir, K., Leidinger, M., Ofori‐Amanfo, G. K., Fritchie, K., Velu, S. E., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27928 · Cited by 13

Targeting autophagy in pancreatic cancer: The cancer stem cell perspective

Troumpoukis, D., Papadimitropoulou, A., Charalampous, C., Kogionou, P., Palamaris, K., Sarantis, P., & Serafimidis, I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1049436 · Cited by 12

Phosphorylation and specific DNA improved the incorporation ability of p53 into functional condensates

Chen, Q., Wu, Y., Dai, Z., Zhang, Z., & Yang, X. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123221 · Cited by 12

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

Zonneville, J., Wang, M., Alruwaili, M., Smith, B. E., Melnick, M., Eng, K. H., Melendy, T., Park, B. H., Iyer, R. V., Fountzilas, C. K., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02370-0 · Cited by 13

Elevated serum expression of p53 and association of TP53 codon 72 polymorphisms with risk of cervical cancer in Bangladeshi women

Mostaid, M. S., Mumu, S. B., Haque, M. A., Sharmin, S., Jamiruddin, M. R., Rahman, G. M. S., & Reza, H. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261984 · Cited by 12

Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study

Wang, H., Wang, Z., Wang, Z., Li, X., Li, Y., Yan, N., Wu, L., Liang, Y., Wu, J., Song, H., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1016-8 · Cited by 11

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

Liu, Z., Yang, Y., Sun, X., Ma, R., Zhang, W., Wang, W., Yang, G., Wang, H., Zhang, J., Wang, Y., et al. (2024) · Molecules · doi:10.3390/molecules29030725 · Cited by 11

Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review

Debnath, A., & Mazumder, R. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096289260240311062343 · Cited by 11

Prognostic impact of ‘multi-hit’ versus ‘single-hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases

Badar, T., Nanaa, A., Atallah, E. L., Shallis, R. M., Craver, E. C., Li, Z., Goldberg, A. D., Saliba, A. N., Patel, A. A., Bewersdorf, J. P., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285000 · Cited by 13

Reciprocal interactions between lncRNAs and MYC in colorectal cancer: partners in crime

Lei, Z., Zhu, Z., Yao, Z., Dai, X., Dong, Y., Chen, B., Wang, S., Wang, S., Bentum‐Ennin, L., Jin, L., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06918-w · Cited by 11

Rational Design and Immunological Mechanisms of Circular RNA-Based Vaccines: Emerging Frontiers in Combating Pathogen Infection

Zhang, Y., Jin, S., Zuo, Z., Liu, S., Xu, J., Yang, C., Wan, P., Xun, L., Luo, M., Yang, F., et al. (2025) · Vaccines · doi:10.3390/vaccines13060563 · Cited by 10

TP53 gene rs1042522 allele G decreases neuroblastoma risk: a two-centre case-control study

Zhang, J., Yang, Y., Li, W., Yan, L., Zhang, D., He, J., & Wang, J. (2019) · Journal of Cancer · doi:10.7150/jca.27482 · Cited by 10

TP53 genetic polymorphisms and susceptibility to cervical cancer in Bangladeshi women: a case–control study

Apu, M. N. H., Rashed, A. Z. M., Bashar, T., Rahman, M. M., & Mostaid, M. S. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05523-2 · Cited by 10

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

Kanagal‐Shamanna, R., Bravo, G. M., Katsonis, P., Sasaki, K., Class, C. A., Jabbour, E. J., Sallman, D. A., Hunter, A. M., Benton, C. B., Chien, K. S., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00446-y · Cited by 10

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes

Yabe, M., Omarbekova, A. Z., Hsu, M., May, H., Arcila, M. E., Liu, Y., Doǧan, A., Brunner, A. M., Nardi, V., Hasserjian, R. P., et al. (2021) · Cancers · doi:10.3390/cancers13215502 · Cited by 9

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma

Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., Cheng, D., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04742-y · Cited by 11

Virtual screening using covalent docking to find activators for G245S mutant p53

Omar, S. I., Lepre, M. G., Morbiducci, U., Deriu, M. A., & Tuszyński, J. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200769 · Cited by 10

TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer

Chapman, L. O., Ledet, E. M., Barata, P. C., Cotogno, P., Manogue, C., Moses, M. W., Christensen, B. R., Steinwald, P., Ranasinghe, L., Layton, J. L., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.10.022 · Cited by 10

Gut microbiome alters functions of mutant p53 to promote tumorigenesis

Lau, H. C.-H., & Yu, J. Q. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00336-y · Cited by 10

Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion

Guo, A. K., Itahana, Y., Seshachalam, V. P., Chow, H. Y., Ghosh, S., & Itahana, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01124-9 · Cited by 10

Gaining insights into relevance across cancers based on mutation features of TP53 gene

Mei, Y., Liang, D., Wang, T., & Yu, D. S. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101165 · Cited by 10

Nanocarriers for photodynamic-gene therapy

de Santana, W. M. O. S., Surur, A. K., Momesso, V. M., Lopes, P. M., Santilli, C. V., & Fontana, C. R. (2023) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2023.103644 · Cited by 10

Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues

Zhao, C., Wang, H., Zhan, W., Lv, X., & Ma, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00079 · Cited by 9

Drugging p53: Barriers, Criteria, and Prospects

Song, H., Xiao, S., Wu, J., & Lu, M. M. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0837 · Cited by 9

Illudin S inhibits p53-Mdm2 interaction for anticancer efficacy in colorectal cancer

Lee, Y. S., Lee, Y. Y., Park, J., Maksakova, A., Seo, D., Kim, J., Yeom, J. E., Kim, Y., Kim, C., Ryoo, R., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117795 · Cited by 11

Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities

Annor, G. K., Elshabassy, N., Lundine, D., Conde, D.-G., Xiao, G., Ellison, V., & Bargonetti, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.772315 · Cited by 9

Concurrent Activation of Both Survival-Promoting and Death-Inducing Signaling by Chloroquine in Glioblastoma Stem Cells: Implications for Potential Risks and Benefits of Using Chloroquine as Radiosensitizer

Müller, A., Weyerhäuser, P., Berte, N., Jonin, F., Lyubarskyy, B., Sprang, B., Kantelhardt, S. R., Salinas, G., Opitz, L., Schulz‐Schaeffer, W., et al. (2023) · Cells · doi:10.3390/cells12091290 · Cited by 9

Synthesis of RNA-based gene regulatory devices for redirecting cellular signaling events mediated by p53

Huang, X., Wang, M., Liu, Y., & Gui, Y. (2021) · Theranostics · doi:10.7150/thno.55856 · Cited by 9

Mechanistic insight into the destabilization of p53TD tetramer by cancer-related R337H mutation: a molecular dynamics study

Yu, Y., Dong, X., Tang, Y., Li, L., & Wei, G. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp05670k · Cited by 9

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rahmé, R., Braun, T., Manfredi, J. J., & Fenaux, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041152 · Cited by 9

Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo

Klimovich, B., Stiewe, T., & Timofeev, O. N. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1693748 · Cited by 9

Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes

Dong, X., Huang, D., Yi, X., Zhang, S., Wang, Z., Yan, B., Sham, P. C., Chen, K., & Li, M. J. (2020) · Communications Biology · doi:10.1038/s42003-019-0736-4 · Cited by 9

Charting the regulatory landscape of TP53 on transposable elements in cancerPreprint

Qu, X., Liang, Y., McCornack, C. R., Xing, X., Schmidt, H. K., Tomlinson, C., Fronick, C. C., Belter, E. A., Macias-Velasco, J. F., & Wang, T. (2025) · Genome Research · doi:10.1101/gr.279398.124 · Cited by 9

Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia

GÜNGÖRDÜ, Ş., & Aptullahoğlu, E. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01473-9 · Cited by 8

Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis

Lin, Y., Ku, C., Wuputra, K., Wu, D., & Yokoyama, K. K. (2024) · Cells · doi:10.3390/cells13191648 · Cited by 8

Structural dynamics of the wild-type p53 DNA-binding domain and hotspot mutants reveal oncogenic conformational shifts

Zhao, Z., Wang, G., Wu, X., & Qian, Z. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp01257k · Cited by 8

Disruption of tp53 leads to cutaneous nevus and melanoma formation in Xenopus tropicalis

Ran, R., Li, L., Shi, Z., Liu, G., Jiang, H., Fang, L., Xu, T., Huang, J., Chen, W., & Chen, Y. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13301 · Cited by 7

The SWIB/MDM2 motif of UBE4B activates the p53 pathway

Wu, H. H., Leng, S., Abuetabh, Y., Sergi, C. M., Eisenstat, D. D., & Leng, R. P. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.02.002 · Cited by 8

G × E interactions as a basis for toxicological uncertainty

Suciu, I., Pamies, D., Peruzzo, R., Wirtz, P. H., Smirnova, L., Pallocca, G., Hauck, C. R., Cronin, M., Hengstler, J. G., Brunner, T., et al. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03500-9 · Cited by 15

High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling

Wander, P., Arentsen-Peters, S. T. C. J. M., Vrenken, K. S., Pinhanços, S. S., Koopmans, B., Dolman, M. E. M., Jones, L., Castro, P. G., Schneider, P., Kerstjens, M. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030638 · Cited by 8

Unraveling the human protein atlas of metastatic melanoma in the course of ultraviolet radiation-derived photo-therapy

Konstantakou, E. G., Velentzas, A. D., Anagnostopoulos, A. K., Giannopoulou, A. F., Anastasiadou, E., Papassideri, I. S., Voutsinas, G. E., Tsangaris, G. T., & Stravopodis, D. J. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.11.015 · Cited by 8

Functional characterization of the p53 “mutome”

Kotler, E., Segal, E., & Oren, M. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1511207 · Cited by 8

Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status

Brenna, C. T. A., Michaeli, O., Wasserman, J. D., & Malkin, D. M. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001982 · Cited by 8

ROS, Redox Regulation, and Anticancer Therapy

Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_9 · Cited by 7

Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses

Li, J., Zhang, S., Wang, B., Dai, Y., Wu, J., Liu, D., Liang, Y., Xiao, S., Wang, Z., Wu, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101976 · Cited by 7

Chemotherapy Options for Locally Advanced Gastric Cancer: A Review

Semenova, Y. M., Kerimkulov, A., Uskenbayev, T., Zharlyganova, D., Shatkovskaya, O., Sarina, T., Manatova, A., Yessenbayeva, G. A., & Adylkhanov, T. A. (2025) · Cancers · doi:10.3390/cancers17050809 · Cited by 8

Programmable protein stabilization with language model-derived peptide guides

Hong, L., Ye, T., Wang, T., Srijay, D., Liu, H., Zhao, L., Watson, R., Vincoff, S., Chen, T., Kholina, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58872-6 · Cited by 8

Heterogeneity in outcomes of TP53 ‐mutated myeloproliferative neoplasms based on disease phenotype and mutational status

Badar, T., Foran, J. M., Bewersdorf, J. P., Wang, Y., Coltoff, A. R., Kettani, M. E., Shah, K. J., Oliva, F. D., Lin, C., JAMY, O. H., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20187 · Cited by 8

AI-HOPE-TP53: A Conversational Artificial Intelligence Agent for Pathway-Centric Analysis of TP53-Driven Molecular Alterations in Early-Onset Colorectal Cancer

Yang, E.-W., Waldrup, B., & Velazquez-Villarreal, E. I. (2025) · Cancers · doi:10.3390/cancers17172865 · Cited by 9

Targeting cancer-specific mutations with RNA-triggered chromatin shredding

Zeng, J., Cheng, Z., Chen, H., Wang, Z., Thompson, J., Crosby, K. T., Han, H., Singhal, A., Ngo, W., Xia, C., et al. (2026) · Nature · doi:10.1038/s41586-026-10738-7 · Cited by 8

p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications

Benitez, D. A., Cumplido-Laso, G., Olivera-Gómez, M., Pino, N. D. V.-D., Díaz-Pizarro, A., Mulero‐Navarro, S., Román-García, A., & Carvajal-González, J. M. (2024) · Biomedicines · doi:10.3390/biomedicines12071453 · Cited by 9

Computational simulations and experimental validation of structure- physicochemical properties of pristine and functionalized graphene: Implications for adverse effects on p53 mediated DNA damage response

Basheer, F., Melge, A. R., Sasidharan, A., Nair, S. V., Manzoor, K., & Mohan, C. G. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.10.106 · Cited by 7

High ROBO3 expression predicts poor survival in non-M3 acute myeloid leukemia

Cai, Z., Wei, J.-F., Chen, Z., & Wang, H. (2021) · Experimental Biology and Medicine · doi:10.1177/1535370220988246 · Cited by 7

What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?

Wang, C., & Sallman, D. A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000569 · Cited by 8

p53-Mediated Indirect Regulation on Cellular Metabolism: From the Mechanism of Pathogenesis to the Development of Cancer Therapeutics

Wang, C.-Y., & Chao, C.-H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.895112 · Cited by 7

USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer

Yang, D., Feng, Y., Lu, H., Chen, K., Xu, J., Li, P., Wang, T., Xia, D., & Wu, Y. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200292 · Cited by 8

Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers

Malhotra, L., Singh, A., Kaur, P., & Ethayathulla, A. S. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2435060 · Cited by 7

Moving From Mutation to Actionability

Colombo, I., Kurnit, K. C., Westin, S. N., & Oza, A. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199665 · Cited by 7

Mutational landscape of TP53 and CDH1 in gastric cancer

Cai, H.-Q., Zhang, L., Fu, L.-M., Xu, B., & Jiao, Y. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i2.276 · Cited by 9

Targeting mutant p53 for cancer therapy

Oren, M., Tal, P., & Rotter, V. (2016) · Aging · doi:10.18632/aging.100992 · Cited by 23

Mutant p53 in Cancer Progression and Targeted Therapies

Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 230

Targeting Therapies for the p53 Protein in Cancer Treatments

Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84

p53: from understanding its structure to advances in therapeutic targeting

Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29

Molecularly targeted therapies for p53-mutant cancers

Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2575-0 · Cited by 82